The fetus has an absolute requirement for the n-3/n-6 fatty acids and docosahexaenoic acid (22:6 n-3; DHA) in particular is essential for the development of the brain and retina. Most of the fat deposition in the fetus occurs in the last 10 weeks of pregnancy. The likely rate of DHA utilisation during late pregnancy cannot be met from dietary sources alone in a significant proportion of mothers. De novo synthesis makes up some of the shortfall but the available evidence suggests that the maternal adipose tissue makes a significant contribution to placental transport to the fetus. The placenta plays a crucial role in mobilising the maternal adipose tissue and actively concentrating and channelling the important n-3/n-6 fatty acids to the fetus via multiple mechanisms including selective uptake by the syncytiotrophoblast, intracellular metabolic channelling, and selective export to the fetal circulation. These mechanisms protect the fetus against low long-chain polyunsaturated fatty acid (LCPUFA) intakes in the last trimester of pregnancy and have the effect of reducing the maternal dietary requirement for preformed DHA at this time. As a result of these adaptations, small changes in the composition of the habitual maternal diet before pregnancy are likely to be more effective in improving LCPUFA delivery to the fetus than large dietary changes in late pregnancy. There is little evidence that DHA intake/status in the second half of pregnancy affects visual and cognitive function in the offspring, but more studies are needed, particularly in children born to vegetarian and vegan and mothers who may have very low intakes of DHA.
Importance of fatty acids to the fetus
Fatty acids are required by the developing fetus as a source of energy, to maintain the fluidity, permeability and conformation of membranes and as precursors of important bioactive compounds such as the prostacyclins, prostaglandins, thromboxanes and leukotrienes ( Figure 1 ). All fatty acids can act as an energy source, but the structural and metabolic functions primarily require the polyunsaturated fatty acids. The human body cannot synthesise fatty acids with double bonds three (n-3) or six (n-6) carbons from the n terminus and these structures must be obtained from the diet either as linoleic (18:2 n-6; LA) and a-linolenic (18:3 n-3; aLN), known as the essential fatty acids, or their long-chain polyunsaturated fatty acid (LCPUFA) derivatives, of which, dihomogamma linolenic (18:3 n-6; DGLA), arachidonic acid (20:4 n-6; AA), eicosapentaenoic (20:5 n-3; EPA) and docosahexaenoic acid (22:6 n-3; DHA) are metabolically the most important ( Figure 1 ). While the LCPUFA are not strictly essential in the diet, it is these that actually perform the essential functions underpinning key developmental outcomes and there is uncertainty as to whether there is sufficient enzymatic capacity to satisfy the high demand experienced during fetal and early postnatal growth. The availability of the PUFA/LCPUFA to the fetus depends not only on the maternal dietary intake but also on the function of the placenta and the many physiological and biochemical adaptations that occur during pregnancy. An understanding of the interaction between these is essential to the setting of appropriate dietary guidelines for pregnancy.
The fatty acid composition of the maternal diet during pregnancy is thought to affect a number of pregnancy outcomes including the rate of growth in utero (Carlson et al, 1992; Smuts et al, 2003) and the length of gestation (Olsen et al, 2000; Olsen & Secher, 2002) , but the outcomes most often studied in relation to LCPUFA in early life are visual and intellectual development, largely as a result of the observation that tissues such as the brain and retina require a high concentration of DHA to function properly (Innis, 1991) . Although the brain of the newborn has a relatively high concentration of DHA, the absolute accretion during in utero life is small. The striking thing about in utero LCPUFA accretion is the very high concentration of DHA and AA in the fetal adipose tissue compared to maternal adipose tissue ( Figure 2 ) and the fact that 50 times more DHA is stored in the adipose tissue than is deposited in the fetal brain during in utero life (Figure 3) . Within a few hours of birth, the adipose tissue stores of the newborn begin to turn over at a high rate (Van Duyne & Havel, 1959) and the stored DHA is largely used up in the first 2 months of postnatal life if the diet is devoid of preformed DHA (Farquharson et al, 1993) . Therefore, the purpose of this adipose store of LCPUFA would appear to support processes such as brain and retinal development during the critical first months of postnatal life. This suggests that the in utero requirement for DHA is likely to be complicated by its interaction with postnatal nutritional status. If the baby has a good supply of DHA in the first months of life, then its adipose stores may not be critical, but if it has a poor supply because it is given formula milk without added LCPUFA, or the mother's breast milk is poor in LCPUFA, or the baby does not feed well on any diet, then the availability in utero and the amount already laid down in the adipose tissue of the newborn may be critical.
The total in utero accretion of DHA in the fetus is around 10 g. Most of this is deposited in the last 10 weeks of pregnancy and much of it is to be found in the adipose tissue of the newborn (Figure 3 ). The DHA deposited in fetal fat may be considered as conditionally essential for pregnancy as it is not actually functional during in utero life, but in practical terms it may or may not be optional as it is an obligatory accompaniment to the normal deposition of adipose stores in the fetus. The adult human brain and retina maintains a high concentration of DHA even in the absence of the elevated concentration of DHA found in the fetal cord blood, therefore it is likely that the fetal brain and retina take priority, with the remainder being left to the adipose tissue. A metabolic cost that has to be met before any DHA is available to the fetus is the obligatory loss of DHA during normal fatty acid oxidation in the mother and fetus. The theoretical rate of oxidation can be calculated from the rate of maternal energy expenditure (9453 MJ/day (Butte, 2000) ), the proportion of that energy derived from fat (30% (Butte, 2000) ) and the energy content of fat (39 kJ/g). The final part of the calculation, and the most difficult to estimate, requires information on the proportion of DHA in the oxidised fat. The fetus preferentially utilises carbohydrate for its energy needs (Sparks et al, 1983) , while selectively channelling DHA into the tissues, therefore most of the DHA oxidation is likely to occur in the mother and it is the maternal composition that is most relevant. Assuming that the oxidised fat is derived from the maternal adipose Figure 1 Pathways of chain elongation and desturation of the essential fatty acids, LA (18:2 n-6) and aLN (18:3 n-3) to produce their LCPUFA derivatives (Sprecher & Chen, 1999) , of which, DGLA (18:3 n-6), AA (20:4 n-6), EPA (20:5 n-3) and DHA (22:6 n-3) are metabolically the most important. These metabolites are the precursors for the groups 1, 2 and 3 prostanoids and leukotrienes, they are important in the structural integrity of membranes. DHA in particular is thought to be required for normal brain and retinal development within the fetus and neonate. Figure 2 Fatty acids may be found in the blood and tissues linked to other molecules by ester bonds; triglyceride (TG), phospholipid (PL) and cholesterol ester (CE); or as non-esterified fatty acids NEFA. AA and DHA as a proportion of total fatty acids are shown for the diet of pregnant mothers (Lakin et al, 1998) , 1 the adipose tissue (Leaf et al, 1995) , 2 maternal and cord blood plasma phospholipids (Otto et al, 1997), 3 triglyceride (Berghaus et al, 2000) , 4 cholesterol ester (Hoving et al, 1994) , 5 and NEFA (Benassayag et al, 1999) , 6 the placental microvillous and basal membranes (Powell et al, 1999) , 7 and adipose tissue and brain at birth (Clandinin et al, 1981) . Figure 3 The theoretical rate of oxidation was calculated from the rate of maternal energy expenditure (9453 MJ/day), the proportion of that energy derived from fat (30%), the energy content of fat (39 kJ/g) (Butte, 2000) and the proportion of DHA in the oxidised fat (0.1% DHA; Figure 2 ). The DHA content of fetal tissues was calculated from the lean mass (calculated as body weight minus the weight of fat, skeleton and skin (Widdowson, 1974) ), the fat mass (Widdowson, 1974) and the weight of the placenta (Hytten, 1974 ) and brain (Clandinin et al, 1980) and the fat and DHA concentration of the brain (Clandinin et al, 1980; Jamieson et al, 1999) , placenta (Widdowson & Spray, 1951; Lakin et al, 1998) and adipose tissue (Clandinin et al, 1981) . For the purposes of the calculation the DHA content of the fetal lean tissue, blood vessels, etc, was assumed to be the same as the placenta. The rate of accretion in the brain and placenta is very small (shown above oxidation and accumulation in the fat and lean tissue) relative to the other components. The average reported daily dietary intake of DHA in different groups (see text) is shown on the right y-axis.
tissue (0.1% DHA; Figure 2 ), the total rate of oxidation would be 90 mg/day. It could theoretically be greater than this if the oxidised fatty acid were mainly derived from the maternal diet, which typically has a higher concentration of DHA (Figure 2 ), but the likelihood is that much of this is preferentially conserved and directed to the placenta. On the basis of these figures, a reasonable estimate for the average rate of DHA utilisation in late pregnancy is probably around 200 mg/day although the figure close to term is greater (Figure 3) . However, the rate of fetal DHA utilisation in a typical omnivore pregnancy is not necessarily equal to the fetal requirement: If the mother's diet and adipose stores were poor in DHA, then the amount lost during fat oxidation would be reduced as would the amount stored in the fetal adipose tissue. Furthermore, the rate of fetal utilisation is not necessarily equal to the maternal dietary requirement. The n-3/n-6 LCPUFA available to the fetus can also be derived from the maternal adipose tissue stores, and by de novo synthesis within the mother, the placenta or the fetus from the relevant essential fatty acid precursor.
Maternal diet
The average omnivore dietary intake of DHA has been estimated in several countries including the UK (220 mg/ day) (Lakin et al, 1998) , Canada (160 mg/day) (Innis & Elias, 2003) and Norway (300 mg/day) (Helland et al, 2001) . These average intakes of DHA are in the same range as the likely combined rate of maternal and fetal DHA utilisation, but within populations there are much lower and higher intakes. Vegetarians make up a significant proportion of women of childbearing age in Europe (11-12% in the UK (Henderson et al, 2002) ) and the majority of the population in countries such as India. This group is of particular concern as the exclusion of meat or fish from the diet can result in very low intakes of DHA. In some studies, these have been reported as 'zero' or 'trace' (Sanders & Reddy, 1992; Reddy et al, 1994) , but in reality it is very difficult to exclude DHA from the diet completely as it is found in significant amounts in eggs but also in measurable amounts in highly processed foods, which may contain small amounts of eggs and other DHA containing raw ingredients. We previously recorded an intake of around 10 mg/day (Lakin et al, 1998) in vegetarian women, but more recently have measured higher intakes (30 mg/day) using a more comprehensive database and improved questionnaire (Masson et al, 2003) . At the other end of the spectrum, women consuming diets dominated by marine products or regularly ingesting marine oil supplements can achieve very high intakes of DHA (41000 mg/ day) (Helland et al, 2001 ). An important fact when balancing intake against deposition is that fetal DHA deposition is heavily skewed towards the end of pregnancy; therefore, while the average rate of deposition in late pregnancy may be met by the dietary intake in the majority of women, the rate of deposition close to term may exceed even relatively high maternal dietary intakes of DHA ( Figure 3 ).
Synthesis of LCPUFA
DHA and AA can be synthesised in human tissues from their essential fatty acid precursors (Carnielli et al, 1996; Salem et al, 1996; Sprecher & Chen, 1999) and feto-placental synthesis of AA and DHA has been proposed as one mechanism to explain the higher concentrations of these LCPUFA in the fetal circulation (Figure 2 ). Clark and colleagues (Cho et al, 1999) have measured delta-5 desaturase and delta-5 desaturase mRNA in human placental tissue although the levels were relatively low compared to other tissues and other workers have been unable to detect any delta-6 or delta-5 desaturase activity in human placental tissue (Chambaz et al, 1985) . Similarly, two studies in the perfused placenta demonstrated no detectable chain elongation and desaturation of either LA or aLN (Booth et al, 1981; Haggarty et al, 1997) . There is one report of incorporation of 14 C from labelled acetate into AA in slices of human placenta (Zimmermann et al, 1979) but taken overall, there appears to be little evidence of significant augmentation of AA and DHA supply to the fetus by placental chain elongation and desaturation. There is, however, more convincing evidence for LCPUFA synthesis in the fetal tissues. Stable isotope studies carried out in vivo have demonstrated that the premature human infant synthesises both AA and DHA at an age when they would still developmentally be dependent on the placenta (Carnielli et al, 1996; Salem et al, 1996) . It has also been deduced from these tracer studies that the rate of AA synthesis is significantly greater than that for DHA. Additional circumstantial evidence that the human infant is better able to synthesise AA than DHA comes from the observation that the concentration of DHA in the neonatal brain is dependent on the intake of preformed DHA, while there is little effect of AA intake on the brain concentration (Farquharson et al, 1993; Makrides et al, 1994; Jamieson et al, 1999) . This difference in synthesis is consistent with the biochemical pathways involved as the final step in the synthesis of DHA is considerably more complex than that for AA (Figure 1 ) in that it requires the participation of enzymes in both peroxisomes and the endoplasmic reticulum as well as the controlled movement of fatty acids between these two cellular compartments (Sprecher & Chen, 1999) . However, if DHA synthesis from EPA were more efficient than that from aLN, it may be appropriate to include some fraction of dietary EPA in a calculation of ingested 'DHA equivalents'. EPA is often present in similar amounts to DHA in omnivore diets; therefore, if its conversion to DHA were very efficient (see below) it would effectively double the intake of 'DHA equivalents' from the diet. EPA is also present in vegetarian diets, but unfortunately the ratio to DHA is lower than in omnivore diets.
Whatever the precursor used, it is not yet possible to factor the rate of synthesis into any balance equation as it has proved difficult to estimate the absolute rates of conversion in vivo even in highly sophisticated tracer studies.
Maternal stores
In the course of pregnancy, the mother deposits approximately the same weight in fat (3500 g) as the entire weight of the average newborn (Hytten, 1974) and the timing of that deposition is closely synchronised with the timing of fetal fat accretion (Figure 4 ). An appreciable amount of DHA is stored in the maternal adipose tissue although it can vary over a wide range depending on the habitual dietary intake of n-3 fatty acids. Omnivores typically have DHA stores of around 19 g in the adipose tissue, although high levels of fish oil supplementation (10 g/day for 41 y) can result in DHA stores in excess of 100 g (calculated from the DHA content of human adipose tissue (Leaf et al, 1995) and a body fat content of 15 kg (Frayn, 1996) plus 3.5 kg stored in the course of pregnancy (Hytten, 1974) ). On typical omnivore diets, the concentration of DHA in the adipose tissue is relatively low (0.1% of total fatty acids) and it would be necessary to mobilise all the maternal adipose tissue in order to make the entire 19 g fully available to the developing fetus. Maternal body fat increases linearly until around 30 weeks of gestation after which a modest net loss occurs (Hytten, 1974) . This period of net mobilisation corresponds to an exponential increase in fetal fat during which 94% of all fat deposition in the fetus occurs (Widdowson, 1968) . Although the net loss of maternal fat is small, the very high fasting lipid levels suggest that the maternal stores are turning over much faster than in the nonpregnant state. Also, the overall proportion of fat oxidised at this time appears to be reduced in the pregnant mother (Butte, 2000) implying that the purpose of this mobilisation is to provide fatty acids for the fetus. The maternal circulating concentrations of triacylglycerol (TG) (Darmady & Postle, 1982) , phospholipids (PL) and nonesterified fatty acid (NEFA) (McDonald et al, 1975) , all increase throughout gestation ( Figure 5 ) and this is particularly striking for maternal TG, which increases 2.5-fold over the course of gestation (Darmady & Postle, 1982) . Perhaps more important is the constancy of this level throughout the day. Even in the fasted state, the pregnant woman has a TG concentration (Darmady & Postle, 1982) , which is almost twice the postprandial peak TG in a nonpregnant individual following the consumption of a high-fat meal (Frayn, 1996) .
Whatever the relative contribution of maternal stores and maternal diet, it is not sufficient to simply make this mixture of fatty acids available to the fetus. Because of the relatively low concentration of fatty acids such as DHA in the maternal adipose tissue and diet (Figure 2) , there must also be discrimination mechanisms in the placenta and/or fetus capable of actively selecting the n-3 and n-6 fatty acids for uptake and retention.
Role of the placenta
The fetal liver has the ability to synthesise fatty acids de novo (Dunlop & Court, 1978) , but much of fetal lipid is derived from the maternal circulation via the placenta and all of the crucial n-3 and n-6 fatty acid structures acquired by the fetus have to cross the placenta. Comparison of the concentrations of two of the most important fatty acids (AA and DHA) 
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Change in maternal fat mass (g) Figure 4 Change in maternal (Hytten, 1974) and fetal (Widdowson, 1968 ) body fat with gestational age during the fetal period (9 weeks to term) when the fetus is dependent on the placenta for its supply of nutrients. Gestational age (weeks)
Non pregnant post-prandial triglyceride peak TG Figure 5 Percentage change with state of gestation in the concentration of maternal circulating plasma TG (Darmady & Postle, 1982) , PL and NEFA (McDonald et al, 1975) relative to prepregnancy value; typical maximum value for the increase in plasma triglyceride in a nonpregnant individual following a high fate metal (Frayn, 1996) is indicated.
Placental function and fatty acid requirements P Haggarty in the mother and fetus indicate a much higher concentration of these LCPUFA in all the major lipid classes in the fetal blood and tissues (Figure 2 ). This selective increase in the concentration of LCPUFA, and DHA and AA in particular, in the fetus is known as 'biomagnification' (Crawford et al, 1976) and the time at which this manifests also appears to be synchronised with the maximum fetal demand. Longitudinal data on maternal and umbilical blood phospholipid fatty acid composition from Al et al (1995 Al et al ( , 2000 indicate that, as with total fat deposition in the fetus, DHA as a percent of total fatty acids in the fetal blood increases exponentially after around 20 weeks gestation. This appears to be a general phenomenon with the DHA percent also increasing in the cholesterol ester (CE) fraction and AA, LA and aLN increasing in the CE and TG fractions at this time (Hoving et al, 1994) . This trans-placental gradient is critical to the delivery of n-3/ n-6 fatty acids to the fetus and there are multiple mechanisms within the placenta to bring it about. During the fetal period, which lasts from the ninth week of gestation until term, the fetus is entirely dependent on the placenta for its supply of nutrients. The human placenta is a hemochorial, villous type where the maternal blood enters the intervillous space via the spiral arteries and flows directly around the terminal villi without any intervening maternal vessel wall (Kaufmann & Scheffen, 1998) . The effective barrier between the maternal and fetal circulation is provided by a thin trophoblastic cover in the form of a syncytium (a single cell or cytoplasmic mass containing several nuclei in which the cytoplasm of constituent cells is continuous; OED), known as the syncytiotrophoblast. Any substance crossing between the maternal and fetal circulation has to pass through this barrier that consists of two membranes: microvillous facing the maternal blood and basal facing the fetal blood.
Although there is a large increase in circulating esterified fatty acid (TG in particular) during the period of maximal placental transfer to the fetus (Figure 5 ), all the available evidence suggests that esterified lipids cannot cross the placenta directly, they have to be hydrolysed by lipases first to yield NEFA. The placenta has the capacity to transfer fatty acids in either direction (Hendrickse et al, 1985; Lafond et al, 1994) , but net transfer is normally from the mother to the fetus and this is driven by the relative concentrations of NEFA and its binding sites at the microvillous and basal membranes (Patel et al, 1997; Haggarty, 2002) . The NEFA concentration difference between the maternal and fetal circulation increases throughout gestation until term when the concentration of NEFA in the maternal plasma at term is approximately three times that in the fetal circulation. However, the concentration of its primary carrier protein, albumin, is actually 10-20% higher in the fetal than maternal circulation (Benassayag et al, 1997 (Benassayag et al, , 1999 . Consequently, the ratio of plasma NEFA to albumin on the fetal side of the placenta is around a third of that on the maternal side (Benassayag et al, 1999) , and it is this gradient that drives the maternal to fetal transfer of fatty acids.
The NEFA available at the microvillous membrane for transport to the fetus is derived from both the NEFA released into the maternal blood following mobilisation from maternal adipose tissue and from circulating TG via the action of maternal or placental lipoprotein lipase. The human placental microvillous membrane contains specific binding sites for the lipoporoteins (VLDL, LDL and HDL), which transport TG and other esterified lipid (Cummings et al, 1982; Naoum et al, 1987; Wittmaack et al, 1995) . The presence of lipoprotein lipase activity (Rothwell & Elphick, 1982; Shafrir & Barash, 1987; Kaminsky et al, 1991; Bonet et al, 1992) allows the production of NEFA from TG. The relative contribution of NEFA and TG to total placental flux in human pregnancy is not known, although isotope studies in guinea-pigs indicate that more of the fatty acid in the fetal circulation is obtained from maternal TG than NEFA (Thomas & Lowy, 1987) . In vivo studies in humans have confirmed that fatty acids derived from maternal TG are taken up by the placenta and released into the fetal circulation (Elphick et al, 1978) . The fact that TG increases much more than the other esterified fractions with gestation suggests that this is the major source of esterified fatty acid for the placenta and this is consistent with the finding of Kuhn & Crawford (1986) that there was no detectable uptake from the maternal circulation of 14 C-labelled AA in the form of PL by the perfused human placenta. There is evidence that the placenta itself may play a role in initiating the mobilisation of fatty acid from the maternal adipose tissue in response to fetal needs. Placentally derived leptin is a potent stimulator of lipolysis (Masuzaki et al, 1997; Gomez et al, 1999; Fruhbeck et al, 2001 ) which the human placenta exports into both the maternal and fetal circulation (Linnemann et al, 2000; Hoggard et al, 2001 ). The rate of placental leptin export into the maternal circulation increases with increasing fetal to placental weight ratio (Hoggard et al, 2001) , suggesting that the placenta may modulate its own substrate supply in response to the fetal demand.
Once available at the microvillous membrane, fatty acids have to cross the two lipid bilayers within the syncytiotrophoblast. Fatty acids can rapidly cross lipid bilayers such as those in the syncytiotrophoblast by simple diffusion and partition (Kamp et al, 1995) , although a number of fatty acidbinding proteins (FABPs) have been identified in the membrane and cytoplasm of mammalian cells, which can reversibly and noncovalently bind fatty acids (Glatz & vanderVusse, 1996) . These proteins are upregulated in conditions of increased cellular fatty acid metabolism and are thought to facilitate the transfer across membranes and intracellular channelling of fatty acids (Veerkamp et al, 1991 (Veerkamp et al, , 2000 Glatz & vanderVusse, 1996; Glatz et al, 1997b) . The main membrane-associated FABPs are the plasma membrane fatty acid binding protein (FABPpm) and the fatty acid transfer proteins (FAT/CD36 and FATP). The FAT/CD36 and FATP are thought to span the lipid bilayer and function as fatty acid transporters/translocases, while the peripheral membrane protein FABPpm is thought to act as an extracellular fatty acid acceptor (Glatz & vanderVusse, 1996; Glatz et al, 1997a, b) . Dutta-Roy and colleagues have demonstrated the presence of FAT/CD36 and FATP on both the microvillous and basal membranes of the placenta and the presence of a placenta-specific protein (p-FABPpm) exclusively on the microvillous membrane. They also observed the presence within the syncytiotrophoblast of cytoplasmic binding proteins first identified in the heart (H-FABP) and liver (L-FABP) (Campbell & Dutta-Roy, 1995; Campbell et al, 1998a; Dutta-Roy, 2000) . The largely symmetric arrangement of fatty acid transfer proteins on microvillous and basal membranes and NEFA-binding sites in both circulations suggests the possibility of bidirectional transfer of fatty acids across the syncytiotrophoblast and this is borne out by in vitro (Lafond et al, 1994 (Lafond et al, , 2000 and in vivo studies (Hendrickse et al, 1985) of AA transport.
There is also evidence for selectivity even before the microvillous membrane takes up the fatty acid. It has been reported that the concentrations of AA and DHA in the NEFA fraction of the intervillous space of the placenta are 3-4 times greater than in the maternal blood outside the placenta (Benassayag et al, 1997) . This finding implies that there is significant selectivity by the placental lipase(s) for the release of LCPUFA from the TG; lipoprotein lipase is known to preferentially hydrolyse TG fatty acids in the 2 position, which are generally more unsaturated (Mortimer et al, 1994; Christensen et al, 1995) . Whatever the mechanism, the degree of enrichment of AA and DHA at the microvillous border is sufficient to account for all of the increase in these fatty acids within the fetal circulation (Figure 2 ) without having to invoke any placental selectivity.
FAT/CD36 and FATP do not appear to have any preference for LCPUFA, therefore their presence on both the microvillous and basal membranes allows for the nonselective transfer of fatty acids across both membranes. However, pFABPpm apparently exhibits a hierarchy of binding affinities for different fatty acids with the approximate order being DHAZAAbLA4aLNboleic acid (Campbell et al, 1998a, b; Dutta-Roy, 2000) . Therefore, its presence exclusively on the maternal face of the placenta may help to drive a selective enrichment of LCPUFA in the NEFA mixture imported into the syncytiotrophoblast (Campbell et al, 1998a) .
Apart from the high concentrations of AA and DHA at the microvillous membrane driven by FABPpm and possible selective hydrolysis of TG, there is evidence from in vivo and in vitro studies that placenta can selectively channel LCPUFA to the fetal circulation. When the maternal face of the human placenta is perfused with a mixture designed to mimic the relative concentrations of individual fatty acids observed in vivo in the NEFA fraction of maternal blood in the last trimester of pregnancy the highest selectivity for transfer to the fetal circulation is for DHA with the order of preference being; DHA4AA4aLN4LA (Haggarty et al, 1999) . This in vitro derived selectivity is similar to that determined in vivo on the basis of maternal and cord blood NEFA arterio-venous difference at birth; DHA4AA4olei-c4LA4aLN (Ruyle et al, 1990) . This means that for this particular physiological mixture of fatty acids the placenta will preferentially transfer more DHA to the fetal circulation at the expense of other less important fatty acids. However, there is evidence that this order of selectivity is not fixed, but that it can change with the particular mixture of fatty acids available in the maternal circulation (Haggarty et al, 1999) , which in turn is largely determined by the maternal diet. Recent in vivo evidence from sophisticated tracer studies using 13 C-labelled fatty acids administered to the mother immediately before caesarean section have also shown selective channelling of particular fatty acids to the fetal circulation (Larque et al, 2003) .
A further control point at which selective concentration of individual LCPUFA in the fetal circulation may occur is the form in which fatty acids are exported by the placenta into the fetal circulation and the way in which the fetus metabolises these. Lipase activity and the presence of lipoprotein receptors have only been reported on the microvillous membrane of the placenta, suggesting that the esterified fatty acids in the fetal circulation may not be available to the placenta for reuptake and there is some direct experimental evidence for this (Kuhn & Crawford, 1986) . The preferential incorporation of PUFA/LCPUFA into exported esterified lipids in the placenta (Haggarty et al, 1997; Kuhn & Crawford, 1986 ) and possibly even the fetal liver (Carnielli et al, 1996) would effectively trap these fatty acids within the fetal circulation.
Interaction of placental function with maternal diet
The fatty acid composition of the maternal diet has a direct effect on the availability of individual fatty acids within the fetal circulation (Van Houwelingen et al, 1992; Reddy et al, 1994; Al et al, 1996 Al et al, , 2000 Otto et al, 1997; Lakin et al, 1998; De Vriese et al, 2002) . However, cross-country comparisons of fatty acid concentrations in pregnancy indicate that the gradient of the line relating maternal and cord blood individual fatty acids is greater for DHA than AA (Otto et al, 1997) . Such a finding would be consistent with the greater placental selectivity for DHA compared to AA and/or a greater ability of the fetus to regulate its own levels of AA by de novo synthesis or reuptake by the placenta. The results of in vitro perfusion studies show that placental selectivity for the n-3 fatty acids, aLN and DHA, appears to be relatively unresponsive to changes in the mixture of fatty acids and that selectivity for the critical DHA in particular remains high regardless of the maternal concentration. However, AA does not appear to follow the same pattern as its selectivity increases with an increase in the maternal AA concentration. The sensitivity of AA selectivity to the concentration in the maternal circulation means that both the absolute transfer rate of AA and the relative selectivity for this fatty acid is altered when the maternal concentration changes. The fact that this effect is specific to AA may be related to its important role as a precursor of the prostacyclins, prostaglandins, thromboxanes and leukotrienes produced by the placenta (Kuhn & Crawford, 1986) . Therefore, one possible explanation for the high sensitivity of transport to AA supply may be that the placenta has a minimum requirement for AA to produce these metabolites and that it is only when this requirement is met that the remaining AA becomes available for transfer to the fetal circulation. This possibility of placental utilisation of AA is consistent with the observations that more AA is accumulated in the placenta perfused with higher concentrations of AA (Haggarty et al, 1997 (Haggarty et al, , 1999 . In vivo studies of maternal venous and umbilical veinartery concentration differences measured at caesarean section also indicate that the transfer of LA and DHA across the placenta is largely dependent on the maternal concentration of these fatty acids but that AA transfer to the fetus is proportional to maternal concentration only above a specific maternal concentration and below that concentration there is either no net transfer to the fetus or even net uptake by the placenta of fetal AA (Hendrickse et al, 1985) .
Potentially adverse affects of high LCPUFA intakes
Women are currently advised to consume oily fish during pregnancy partly because of the beneficial effect of such foods on vascular function, but it is generally assumed that this may also be beneficial for the developing fetal brain and retina. However, it is worth noting that very high intakes from marine sources, particularly in the form of supplements, may not be entirely risk free. For example, it has been reported that supplementation of premature infants with marine oils can adversely affect growth, the hypothesis being that this results from an altered balance of n-3 (DGLA and EPA) and n-6 (AA) prostanoid precursors (Carlson et al, 1992) . It is likely, however, that buffering by the maternal adipose tissue and the ability of the placenta to transport AA to and from the fetus will protect it against large variations in maternal dietary intake. More recently, it has been reported that supplementation of mothers with modest levels of DHA resulted in a slight but nonsignificant increase in birth weight and length of gestation (Smuts et al, 2003) , but this supplement did not include EPA. Another concern relates to the other fat-soluble components of foods and supplements of marine origin. Marine oils may contain significant concentrations of vitamin A but also organochlorines which include polychlorinated biphenols (PCBs) and dioxins (Falandysz, 1994; Jacobs et al, 1998) . Levels of PCBs in the environment are generally decreasing (Lackmann, 2002) , but there are reports of a positive association between maternal and cord concentrations of EPA, DHA and PCBs (Grandjean & Weihe, 2003) and concerns have been raised that they may still be harmful to the fetus if ingested in sufficient quantity by the mother (Olsen, 2001) . A particular concern is that, because of their similar physiochemical properties, those physiological mechanisms designed to optimise maternal delivery of n-3 LCPUFA to the fetus may also serve to increase the fetal exposure to organochlorines. The important factor is the trans-placental flux to which the fetus is exposed and it has been suggested that PCBs may be capable of crossing the placenta to a greater extent than previously believed (DeKoning & Karmaus, 2000) . Cord blood levels correlate with maternal adipose levels where the concentrations of these toxins can be 10-100 times higher than other compartments within the body (van der Ven et al, 1992) . While organochlorines may be relatively harmless when stored in the adipose tissue, fat mobilisation increases the plasma concentrations of these toxins (Chevrier et al, 2000; Imbeault et al, 2001 ) and the very high rate of mobilisation of maternal fat stores in the last trimester of pregnancy and the possible remobilisation of neonatal adipose tissue in early life is likely to lead to repeated washing out of these compounds into the circulation, organs and tissues of the fetus and neonate during critical periods of development.
Implications for dietary recommendations
Total maternal lipoprotein lipase activity is reduced in women in late pregnancy and animal models indicate a redistribution of the available activity towards the placenta and away from adipose tissue and liver (Herrera et al, 1988) . Thus, it is likely that the dietary lipid is preferentially available to the placenta. However, a significant proportion of mothers do not ingest sufficient preformed DHA in the last trimester of pregnancy to meet the estimated rate of maternal and fetal DHA utilisation. Chain elongation and desaturation can make up some of the shortfall, particularly when operating over long periods, but the available evidence suggest that at the peak of the fetal requirement in the last trimester the maternal adipose tissue provides a significant proportion of the raw material as low-concentration LCPU-FA. The relative importance of diet and adipose stores to overall trans-placental LCPUFA flux may be inferred from feeding studies, which show that supplementation at the level of 100 mg/day of DHA or 336 mg/day of fish oils (Velzing-Aarts et al, 2001) has no measurable effect on cord blood n-3 concentrations. There are reports of measurable effects on cord blood of supplementation with marine oils but at much higher levels: 2600 mg/day (Connor et al, 1996) and 2700 mg/day of n-3 fatty acids and it appears that intakes of 500-1000 mg/day (3-5 times the normal dietary intake) are necessary before an increase in the n-3 content of the cord can be achieved with late pregnancy supplementation (Velzing-Aarts et al, 2001) . Contrast this with the observation that fairly modest differences between individuals in the n-3 content of their normal diet can have significant effects on the cord blood composition (Otto et al, 1997) .
The concentration of DHA is generally greater in the diet (0.4% in omnivores; Figure 2 ) than it is in the maternal adipose tissue (0.1%; Figure 2 ) and this might suggest that it would be better for the placenta to preferentially utilise the dietary lipid. However, there are good reasons why the use of maternal adipose tissue might present a significant evolutionary advantage. It would ensure a constant supply of substrate to the fetus, free of large diurnal fluctuations corresponding to the timing of maternal meals. It would also protect the fetus against a transiently poor LCPUFA intake during the critical period of fetal growth and may allow mothers to meet the full fetal requirement for LCPUFA while consuming an apparently deficient diet. This process is also relevant to the practical issue of the timing of dietary fatty acid recommendations for pregnancy as it would appear that improvements in LCPUFA delivery in utero are more easily achieved by small changes in the composition of the habitual maternal diet than large changes in late pregnancy. The placenta plays a critical role in this process by selectively enriching the low-concentration LCPUFA supply available in the maternal circulation and channelling it to the fetus, and it may also regulate the process of mobilisation of the maternal adipose tissue. The net result of these processes would be to reduce the maternal dietary requirement for DHA greatly during the crucial last trimester of pregnancy.
The dietary requirement is determined not by the effect of intake on cord blood levels but on its influence on functional outcomes. Observational studies correlating cord blood DHA status at birth and visual and intellectual function either suggest that there is no link (Bakker et al, 1999; Ghys et al, 2002) or they imply a negative association; it has been reported that DHA status is inversely proportional to birth weight (Rump et al, 2001 ), yet there is a wellestablished positive relationship between birth weight and IQ in the general population (Matte et al, 2001; Richards et al, 2001) . However, such observational studies have to be interpreted with caution as cord blood levels are actually the net result of placental supply and fetal utilisation and may not correlate exactly with fetal availability. A better approach is to titrate the intake of DHA against the functional outcome of interest in intervention studies. The effect on visual and intellectual development of supplementation of formula milk with LCPUFA has been extensively studied (Lucas et al, 1992 (Lucas et al, , 1998 Birch et al, 1998; Horwood et al, 2001; Willatts, 2002; Auestad et al, 2003; O'Connor et al, 2003) and, on balance, the evidence suggests that an intake of preformed n-3 LCPUFA may be beneficial. Unfortunately, there are very few studies that deal specifically with supplementation during pregnancy. In the most recent of these, Malcolm et al (2003) reported no effect of maternal DHA supplementation, at a fairly modest level of 100 mg/ day, on visual function (visual evoked potential) measured shortly after birth and at 12-15 months after birth. Helland et al (2001) also observed no effect of supplementation, but at a much higher level (1183 mg/day DHA), on measures of cerebral maturity (electroencephalogram) and cognition (Fagan test) shortly after birth. However, both studies reported observational associations not necessarily related to the supplementation. Malcolm et al reported an association between one component of the measurements of visual response and the cord blood DHA concentration, yet the supplementation did not significantly alter cord blood DHA levels . Helland et al reported an association between the cord blood DHA at birth and one of the measures of function (cerebral maturity), although in this case the cord DHA level was also associated with gestational age, and it is not clear whether this was corrected for in the analysis. Helland et al (2003) in a subsequent study reported a positive effect on IQ at 4 years of the DHA supplementation, although the supplementation period continued throughout lactation, making it difficult to conclude whether the sensitive period was in utero or in early neonatal life when there is already some evidence for a beneficial effect of LCPUFA intake.
Taken overall, there appears to be little clear evidence of a beneficial effect of DHA supplementation/status in the second half of pregnancy on visual and cognitive function in the offspring. It is worth bearing in mind, however, that the relative importance of maternal adipose tissue to fetal supply in late pregnancy may obscure the effects of late supplementation intervention. For a true test of an effect of diet on function, it may be necessary to extend the supplementation period to well before the beginning of the pregnancy. It is also the case that supplementation on top of already adequate omnivore intakes, as in the Helland studies, may not yield any measurable benefit but that very low intakes do result in loss of function. It is the study of very low intakes that are likely to yield the best information on requirements and, although methodically less rigorous than intervention studies, it would be informative in the first instance to simply compare IQ and visual function in children born to vegetarian, vegan and omnivore mothers but as yet there are no reports of such studies.
